Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07329640 |
Synonyms | |
Therapy Description |
Limited information is currently available on PF-07329640, a putative LTBR agonist antibody (Jun 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07329640 | PF07329640|PF 07329640 | Limited information is currently available on PF-07329640, a putative LTBR agonist antibody (Jun 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06448364 | Phase I | PF-06801591 + PF-07329640 PF-07329640 Bevacizumab + PF-07329640 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (LTbR) | Terminated | USA | 1 |